# FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Nonprescription Drugs Advisory Committee Meeting

HILTON WASHINGTON, DC/SILVER SPRING 8727 COLESVILLE ROAD, SILVER SPRING, MARYLAND DECEMBER 14, 2007

### **AGENDA**

The committee will discuss the safety and effectiveness of phenylephrine hydrochloride and phenylephrine bitartrate as OTC oral nasal decongestants.

		Aller
8:00 a.m.	Call to Order and Opening Remarks	Mary E. Tinetti, M.D.
	Introduction of Committee	Chair, Nonprescription Drugs Advisory Committee
	Conflict of Interest Statement	Diem-Kieu H. Ngo, Pharm.D. Designated Federal Official
8:15 a.m.	FDA Introductory Remarks	Susan Johnson, Pharm.D., Ph.D. Associate Director,
		Office of Nonprescription Products, CDER, FDA
FDA PRES	SENTATION	
8:25 a.m.	History of the OTC Drug Review as it Relates to Phenylephrine	Mary S. Robinson, M.S. Regulatory Review Chemist, Division of Nonprescription Regulation Development Office of Nonprescription Products, CDER, FDA
8:35 a.m.	Effectiveness and Safety of Phenylephrine as an OTC Oral Nasal Decongestant	Michael L. Koenig, Ph.D. Interdisciplinary Scientist, Division of Nonprescription Regulation Development Office of Nonprescription Products, CDER, FDA
9:05 a.m.	Statistical Evaluation of Effectiveness Submissions	Stan Lin, Ph.D.  Mathematical Statistician, Division of Biometrics 4 Office of Biostatistics, OTS, CDER, FDA
9:25 a.m.	Clinical Endpoints for Nasal Decongestants	Xu Wang, M.D., Ph.D.  Medical Officer  Division of Pulmonary and Allergy Products  Office of New Drugs, CDER, FDA
9:40 a.m.	Questions/Clarifications	

10:00 a.m. **BREAK** 

## FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Nonprescription Drugs Advisory Committee Meeting

HILTON WASHINGTON, DC/SILVER SPRING 8727 COLESVILLE ROAD, SILVER SPRING, MARYLAND DECEMBER 14, 2007

# AGENDA -CONTINUED-

#### **PETITIONER PRESENTATION**

12:25 p.m. **LUNCH** 

1:25 p.m. Open Public Hearing

2:25 p.m. Questions/Clarifications

10:15 a.m. Background on Decongestants and Leslie Hendeles, Pharm.D. Citizens Petition Professor, Pharmacy and Pediatrics University of Florida 10:35 a.m. Efficacy and Safety of Oral Randy Hatton, Pharm.D. Phenylephrine: Systematic Review Co-Director, Drug Information and Pharmacy and Meta-Analysis Resource Center, Shands Hospital at the University of Florida; Clinical Professor, College of Pharmacy, University of Florida 10:45 a.m. Evaluation of the Statistical Methods Jonathan J. Shuster, Ph.D. Used in the CHPA Meta-Analysis Research Professor, Division of Biostatistics, Department of Epidemiology and Health Policy; Research Biostatistician, General Clinical Research Center, College of Medicine, University of Florida **INDUSTRY PRESENTATION** 11:05 a.m. Introduction **Consumer Healthcare Products Association** (CHPA) 11:10 a.m. Clinical Overview of Two Allergy Melvyn Danzig, Ph.D. Chamber Studies with Phenylephrine Project Director Clinical Research - Allergy/Respiratory Schering-Plough/Merck Pharmaceuticals 11:25 a.m. Understanding Phenylephrine Metabolism, John O'Mullane, Ph.D. Group Vice President, Research and Development Pharmacokinetics, Bioavailability, and Schering-Plough Corporation Activity 11:40 a.m. Safety, Pharmacology & Efficacy, and **CHPA Task Force** Summary

# FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER) Nonprescription Drugs Advisory Committee Meeting

HILTON WASHINGTON, DC/SILVER SPRING 8727 COLESVILLE ROAD, SILVER SPRING, MARYLAND DECEMBER 14, 2007

### **AGENDA** -CONTINUED-

3:00 p.m. **BREAK** 

3:15 p.m.

5:00 p.m.

